Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan

Hepatology Research

Volumn 42, Issue 2, 2012, Pages 131-138

  Ohira, Hiromasa ^a   Takahashi, Atsushi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute presentation; Azathioprine; Fulminant hepatitis; Overlap syndrome; Primary biliary cirrhosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ACUTE LIVER FAILURE; ANTIBODY TITER; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG DOSE REDUCTION; HEP 2 CELL; HUMAN; HUMAN CELL; JAPAN; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LIVING DONOR; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

EID: 84855923011     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00904.x     Document Type: Review

References (70)

1. Abe M, Mashiba T, Zeniya M etal. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011; 46 (9): 1136-41.
2. Onji M, Nonaka T, Horiike N, Moriwaki H, Muto Y, Ohta Y. Present status of autoimmune hepatitis in Japan. Gastroenterol Jpn 1993; 28: 134-8.
3. Toda G, Zeniya M, Watanabe F etal. Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 1997; 26: 1207-12.
4. Seki T, Kiyosawa K, Inoko H etal. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990; 12: 1300-4.
5. Suzuki Y, Ikeda K, Hirakawa M etal. Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis. Dig Dis Sci 2010; 55: 2070-6.
6. Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med Okayama 2008; 62: 217-26.
7. Fujiwara K, Yasui S, Tawada A etal. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res 2011; 41: 133-41.
8. Alzarez R, Berg PA, Bianchi FB etal. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
9. Hennes EM, Zeniya M, Czaja AJ etal. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
10. Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009; 29: 254-61.
11. Yeoman AD, Westbrook RH, Al-Chalabi T etal. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50: 538-45.
12. Neuhauser M, Bjornsson E, Treeprasertsuk S etal. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010; 105: 345-53.
13. Onji M, The Autoimmune Hepatitis Study Group. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res 2011; 41: 497.
14. Okano N, Yamamoto K, Sakaguchi K etal. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003; 25: 263-70.
15. Abe M, Onji M, Kawai-Ninomiya K etal. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 2007; 5: 255-8.
16. Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res 2011; 41: 498-504.
17. Manns MP, Czaja AJ, Gorham JD etal. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
18. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572-7.
19. Zen Y, Harada K, Sasaki M etal. Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis and chronic viral hepatitis? Interobsever histological agreement on trimmed bile ducts. J Gastroenterol 2005; 40: 164-70.
20. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004; 28: 471-8.
21. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006; 59: 246-9.
22. Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 2007; 38: 1669-75.
23. Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011; 46: 378-90.
24. Suzuki Y, Arase Y, Ikeda K etal. Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. J Gastroenterol Hepatol 2004; 19: 699-706.
25. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005; 25: 311-20.
26. Poupon R, Chazouilleres O, Corpechot C etal. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90.
27. Yokokawa J, Saito H, Kanno Y etal. Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol 2010; 25: 376-82.
28. Lohse AW, zum Büschenfelde KH, Franz B etal. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29: 1078-84.
29. Zeniya M, Watanabe F, Morizane T etal. Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model. J Gastroenterol 2005; 40: 1148-54.
30. Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007; 27: 1086-90.
31. Tanaka A, Harada K, Ebinuma H etal. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res 2011; 41: 877-886.
32. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
33. Joshi S, Cauch-Dudek K, Wanless IR etal. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35: 409-13.
34. Kuiper EM, Zondervan PE, Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010; 8: 530-4.
35. Muratori P, Granito A, Pappas G etal. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009; 104: 1420-5.
36. Ozaslan E, Efe C, Akbulut S etal. Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepatogastroenterology 2010; 57: 441-6.
37. Boberg KM, Chapman RW, Hirschfield GM etal. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-85.
38. Kakumu S. Autoimmune hepatitis: diagnostic standards and severity. Nippon Naika Gakkai Zasshi 1999; 88: 584-90 (in Japanese).
39. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816-23.
40. Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 2007; 27: 214-26.
41. Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010; 31: 771-87.
42. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
43. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23: 116-23.
44. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
45. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose and combination with azathioprine compound. Gut 1975; 16: 876-83.
46. Mima S, Sekiya C, Kanagawa H etal. Ursodeoxycholic acid (UDCA) therapy for autoimmune hepatitis. Int Hepatol Commun 1994; 2: 207-12.
47. Nakamura K, Yoneda M, Yokohama S etal. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-5.
48. Miyake Y, Iwasaki Y, Kobashi H etal. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 2009; 3: 556-62.
49. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 1381-6.
50. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9.
51. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-41.
52. Honda M, Orii F, Ayabe T etal. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000; 118: 859-66.
53. Rai T, Ohira H, Tojo J etal. Expression of human glucocorticoid receptor in lymphocytes of patients with autoimmune hepatitis. Hepatol Res 2004; 29: 148-52.
54. Smith DF. Dynamics of heat shock protein 90-progesterone receptor binding and the disactivation loop model for steroid receptor complexes. Mol Endocrinol 1993; 7: 1418-29.
55. Murphy PJ. Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention. Leukemia 2005; 19: 710-12.
56. Wadekar SA, Li D, Periyasamy S, Sánchez ER. Inhibition of heat shock transcription factor by GR. Mol Endocrinol 2001; 15: 1396-410.
57. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003; 178: 339-46.
58. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1676-83.
59. Bergan S. Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements. Biodrugs 1997; 8: 446-56.
60. Montano-Loza AJ, Carpenter HA, Czaja AJ etal. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
61. Yokokawa J, Kanno Y, Saito H etal. Risk factor associated with relapse of type 1 autoimmune hepatitis in Japan. Hepatol Res 2011; 41: 641-6.
62. Chazouillères O, Wendum D, Serfaty L etal. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44: 400-6.
63. Silveira MG, Talwalkar JA, Angulo P etal. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007; 102: 1244-50.
64. Nakanuma Y, Zen Y, Harada K etal. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010; 60: 167-74.
65. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G, Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 2008; 38: 646-57.
66. Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol 2011; 26: 65-71.
67. Ichai P, Duclos-Vallée JC, Guettier C etal. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003.
68. The Japanese Liver Transplantation Society. Liver transplantation in Japan - Registry by the Japanese Liver Transplantation Society. Jpn J Transpl 2010; 45: 621-32 (in Japanese).
69. Sugihara J, Naito T, Ishiki Y etal. A multicenter study on the prognosis and indication of liver transplantation for fulminant hepatitis in Japan: details of decision of the guideline for liver transplantation in Japanese Acute Hepatic Failure Study Group (1996). Kanzo 2001; 42: 543-7 (in Japanese).
70. Mochida S. Fulminant hepatitis: recent problems in Japan. Kanzo 2009; 50: 497-506 (in Japanese).